Evogene reports Q4 EPS (13c), consensus (14c)

Reports Q4 revenue $578M, consensus $910K. CEO Ofer Haviv stated, “The Evogene Group has experienced a transformative year with industry perception of our technology and products translating into growing collaborations with world-leading companies…This collaboration momentum affirms the value of Evogene’s AI tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, built on our CPB platform developed over a decade. Looking forward, we anticipate further partnerships with industry leaders, increased sales of subsidiary products like Casterra’s elite castor varieties and Lavie Bio’s bio-inoculant Yalos, and expansion beyond our current sectors. These efforts not only validate our contributions but also bolster our financial position through various revenue streams, reflected in today’s reported revenues of approximately $5.6M in 2023, compared to approximately $1.7M 2022. We anticipate continued revenue growth for the Evogene Group in 2024.”